A single arm trial of cetuximab, FOLFIRI combined with NK as the second line region in metastatic K-ras positive colorectal cancer: the XQZL001 study

ABSTRACT: Interventions: 1:cetuximab, FOLFIRI combined with NK as the second line remedy Primary outcome(s): disease control rate, DCR;Objective Response Rate Study Design: Case series

DISEASE(S): Colorectal Cancer

PROVIDER: 2668928 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR